We discovered and patented a novel therapeutic strategy to upregulate Polycystin-1 by targeting upstream open reading frames (uORFs) of PKD1 gene, offering a first-in-class approach to treat autosomal dominant polycystic kidney and liver diseases (ADPKD/ADPLD). This uORF-blocking strategy aims to restore PC1 protein dosage and halt cyst formation.